Achieve Life Sciences (ACHV) Interest Expenses (2018 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Interest Expenses of $274000.0 in Q1 2026, up 9.16% on a QoQ basis from $251000.0 in Q4 2025, and up 48.11% year-over-year from $185000.0 in Q1 2025.
Achieve Life Sciences (ACHV) Interest Expenses (2018 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Interest Expenses across 7 years of filings, most recently posting $274000.0 for Q1 2026.
- Quarterly Interest Expenses rose 48.11% year-over-year to $274000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $908000.0 (down 41.49% YoY) and the FY2025 annual result came in at $819000.0, down 62.43% from the prior year.
- Interest Expenses rose to $274000.0 in Q1 2026, from $251000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $813000.0 in Q1 2024 and troughed at $185000.0 in Q1 2025.
- A 5-year average of $465588.2 and a median of $404000.0 in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses jumped 76.24% — and 2025, when it slumped 77.24%.
- Tracing ACHV's Interest Expenses over 5 years: stood at $547000.0 in 2022, then surged by 43.88% to $787000.0 in 2023, then sank by 74.97% to $197000.0 in 2024, then advanced by 27.41% to $251000.0 in 2025, then rose by 9.16% to $274000.0 in 2026.
- Business Quant data shows ACHV's Interest Expenses at $274000.0 in Q1 2026, $251000.0 in Q4 2025, and $192000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 61,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -332,000.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -5.58 Mn |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | 274,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 274,000.00 |
| Mar 31, 2026 | 274,000.00 |
| Dec 31, 2025 | 251,000.00 |
| Dec 31, 2025 | 251,000.00 |
| Sep 30, 2025 | 192,000.00 |
| Sep 30, 2025 | 192,000.00 |
| Jun 30, 2025 | 191,000.00 |
| Jun 30, 2025 | 191,000.00 |
| Mar 31, 2025 | 185,000.00 |
| Mar 31, 2025 | 185,000.00 |
| Dec 31, 2024 | 197,000.00 |
| Dec 31, 2024 | 197,000.00 |
| Sep 30, 2024 | 366,000.00 |
| Sep 30, 2024 | 366,000.00 |
| Jun 30, 2024 | 804,000.00 |
| Jun 30, 2024 | 804,000.00 |
| Mar 31, 2024 | 813,000.00 |
| Mar 31, 2024 | 813,000.00 |
| Dec 31, 2023 | 787,000.00 |
| Dec 31, 2023 | 787,000.00 |